The Hong Kong Stock Exchange shot to the top as the world’s foremost venue for initial public offerings in 2025 and pushes ahead strongly into 2026. Meanwhile, London for example, ...

"Physical AI agtech” could “draw a lot of capital and bring back 'tourist' VC," predicts Antony Yousefian at The First Thirty ...

Elon says Tesla will be one of the companies to make AGI and probably the first to make it in humanoid/atom-shaping form.

Layoffs dominated headlines, yet many of the largest Massachusetts life sciences companies increased headcount. Here's who ...

The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.

Generate:Biomedicines has hit the public markets as the world begins to question the usefulness of AI technology. CEO Mike Nally says biology is the key to unlocking the technology’s full potential.

The developer of Covid-19 vaccine Covaxin, Bharat Biotech is considering an initial public offering that could raise over $500 million, according to sources cited by multiple reports. Discussions are ...

Recent developments in health highlight a volatile market debut, paused drug trials, major IPO launches, and controversial decisions. Generate Biomedicines' shares fell upon Nasdaq entry, while ...

The IPO arena for biotechs has been selectively opening up for later-stage drug startups, but their reception has been uneven.

One IPO and six SPACs came to market this past week, and one major issuer joined the pipeline as February comes to a close.

Generate Biomedicines Inc. shares slumped 21% in the company’s trading debut after it raised $400 million in an initial public offering.

Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a ...